1139 related articles for article (PubMed ID: 27016193)
1. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
[TBL] [Abstract][Full Text] [Related]
2. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
3. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
[TBL] [Abstract][Full Text] [Related]
4. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
Kharbanda S; Smith AR; Hutchinson SK; McKenna DH; Ball JB; Lamb LS; Agarwal R; Weinberg KI; Wagner JE
Biol Blood Marrow Transplant; 2014 Apr; 20(4):581-6. PubMed ID: 24370862
[TBL] [Abstract][Full Text] [Related]
5. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
6. Good engraftment after reduced intensity targeted busulfan-based conditioning and matched related donor hematopoietic cell transplantation in hemoglobinopathies.
Klink M; Felber M; Zeilhofer U; Hauri-Hohl M; Schmugge M; Drozdov D; Güngör T
Pediatr Blood Cancer; 2024 Jul; 71(7):e30988. PubMed ID: 38613166
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
McPherson ME; Hutcherson D; Olson E; Haight AE; Horan J; Chiang KY
Bone Marrow Transplant; 2011 Jan; 46(1):27-33. PubMed ID: 20305698
[TBL] [Abstract][Full Text] [Related]
8. Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen.
Korula A; Pn N; Devasia A; Lakshmi KM; Abraham A; Sindhuvi E; George B; Srivastava A; Mathews V
Biol Blood Marrow Transplant; 2018 Jan; 24(1):103-108. PubMed ID: 29032269
[TBL] [Abstract][Full Text] [Related]
9. Outcome of allogeneic Hematopoietic Stem Cell Transplantation on Diamond-Blackfan anemia using busulfan-based myeloablative regimen.
Behfar M; Koochakzadeh L; Yazdanian N; Salajegheh P; Rostami T; Khodayari-Namini N; Ghavamzadeh A; Hamidieh AA
Turk J Pediatr; 2019; 61(3):407-412. PubMed ID: 31916719
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.
Bernardo ME; Piras E; Vacca A; Giorgiani G; Zecca M; Bertaina A; Pagliara D; Contoli B; Pinto RM; Caocci G; Mastronuzzi A; La Nasa G; Locatelli F
Blood; 2012 Jul; 120(2):473-6. PubMed ID: 22645178
[TBL] [Abstract][Full Text] [Related]
12. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
[No Abstract] [Full Text] [Related]
13. Allogeneic/Matched Related Transplantation for β-Thalassemia and Sickle Cell Anemia.
Bernaudin F; Pondarré C; Galambrun C; Thuret I
Adv Exp Med Biol; 2017; 1013():89-122. PubMed ID: 29127678
[TBL] [Abstract][Full Text] [Related]
14. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
[TBL] [Abstract][Full Text] [Related]
15. Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience.
Patel SA; Allewelt HA; Troy JD; Martin PL; Driscoll TA; Prasad VK; Kurtzberg J; Page KM; Parikh SH
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1722-1728. PubMed ID: 28647558
[TBL] [Abstract][Full Text] [Related]
16. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
17. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
[TBL] [Abstract][Full Text] [Related]
18. Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD.
Levine JE; Wiley J; Kletzel M; Yanik G; Hutchinson RJ; Koehler M; Neudorf S
Bone Marrow Transplant; 2000 Jan; 25(1):13-8. PubMed ID: 10654008
[TBL] [Abstract][Full Text] [Related]
19. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment.
Caocci G; Orofino MG; Vacca A; Piroddi A; Piras E; Addari MC; Caria R; Pilia MP; Origa R; Moi P; La Nasa G
Am J Hematol; 2017 Dec; 92(12):1303-1310. PubMed ID: 28850704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
